Skip to main content

Advertisement

SpringerLink
Log in

Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits

  • Therapeutic Aspects in Autoimmunity
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

About a third of patients with rheumatoid arthritis treated with adalimumab may develop anti-adalimumab antibodies. Anti-adalimumab antibodies are associated with reduced drug levels, loss of drug efficacy, clinical non-response and an increased risk of adverse effects. In case of suspected drug failure and in order to better define clinical efficacy, adalimumab as well as anti-adalimumab antibodies levels should be monitored. Sandwich or indirect enzyme-linked immunoassay is most commonly used for determining adalimumab, while bridging ELISA and antigen-binding test are most useful for determining anti-adalimumab antibodies. Most current assays cannot detect antibodies complexed with the adalimumab; however, methods for dissociation of the complexes using acid/temperature have been developed. The aim of this review is to report on the latest methodology for detecting adalimumab and anti-ADL antibodies, benefits of their detections in clinical practice, as well as expose problematic issues, such as different analytical sensitivity and specificity, standardization and validation. The main problem in measuring adalimumab or anti-ADL antibodies is high drug sensitivity, which can result in false-negative anti-ADL antibodies. Therefore, drug-tolerant assays have been developed. Cell-based assays, such as the reporter gene assay, are recommended for detection of functionally active adalimumab and their neutralizing anti-ADL antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Scheme 1
Scheme 2

Similar content being viewed by others

References

  1. Schaeverbeke T, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford). 2016;55(2):210–20.

    Article  Google Scholar 

  2. Marinari B, et al. Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations. Drug Dev Res. 2014;75(Suppl 1):S11–4.

    Article  CAS  PubMed  Google Scholar 

  3. Maxwell LJ et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015; 4: p. CD005468.

  4. Zisapel M, et al. Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol. 2015;42(1):73–8.

    Article  CAS  PubMed  Google Scholar 

  5. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947–55.

    Article  CAS  PubMed  Google Scholar 

  6. Humira (Adalimumab). Web page. 24.11.2015. www.humira.com.

  7. Remicade (Infliximab). Web page. 24 Aug 2015. www.remicade.com.

  8. Enbrel (Etanercept). Web page. 24 Aug 2015. www.enbrel.com.

  9. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903–11.

    Article  CAS  PubMed  Google Scholar 

  10. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211–5.

    Article  PubMed  Google Scholar 

  11. Mazilu D, et al. Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed Res Int. 2014;2014:702701.

    PubMed  PubMed Central  Google Scholar 

  12. Keiserman M, et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol. 2014;10(8):1049–57.

    Article  CAS  PubMed  Google Scholar 

  13. Jung YO, Kim HA. Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis. Korean J Intern Med. 2012;27(4):378–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Weinblatt ME, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.

    Article  CAS  PubMed  Google Scholar 

  15. Jespers LS, et al. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (NY). 1994;12(9):899–903.

    Article  CAS  Google Scholar 

  16. Radstake TR, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739–45.

    Article  CAS  PubMed  Google Scholar 

  17. Wang SL, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal. 2013;78–79:39–44.

    Article  PubMed  Google Scholar 

  18. Lallemand C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. J Immunol Methods. 2011;373(1–2):229–39.

    Article  CAS  PubMed  Google Scholar 

  19. Eng GP, et al. Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. Arthritis. 2015;2015:784825.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Dekker LJ, et al. An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions. Anal Bioanal Chem. 2011;399(3):1081–91.

    Article  CAS  PubMed  Google Scholar 

  21. van Schouwenburg PA, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–8.

    Article  PubMed  Google Scholar 

  22. van Schouwenburg PA, et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis. 2013;72(10):1680–6.

    Article  PubMed  Google Scholar 

  23. Bloem K, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015;418:29–38.

    Article  CAS  PubMed  Google Scholar 

  24. Hart MH, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372(1–2):196–203.

    Article  CAS  PubMed  Google Scholar 

  25. Pouw MF, et al. Key findings towards optimising adalimumab treatment: the concentration–effect curve. Ann Rheum Dis. 2015;74(3):513–8.

    Article  CAS  PubMed  Google Scholar 

  26. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32(10):1429–35.

    Article  CAS  PubMed  Google Scholar 

  27. Bartelds GM, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther. 2010;12(6):R221.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Bartelds GM, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. van Schouwenburg PA, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol. 2012;32(5):1000–6.

    Article  CAS  PubMed  Google Scholar 

  30. Desvignes C, et al. Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration. Bioanalysis. 2015;7(10):1253–60.

    Article  CAS  PubMed  Google Scholar 

  31. Hock BD, et al. Development of an ELISA based competitive binding assay for the analysis of drug concentration and anti-drug antibody levels in patients receiving adalimumab or infliximab. Ther Drug Monit. 2016;38:32–41.

    Article  CAS  PubMed  Google Scholar 

  32. Ternant D, et al. Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79(2):286–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bartelds GM, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–8.

    Article  CAS  PubMed  Google Scholar 

  34. Grampp G, Felix T. Pharmacovigilance considerations for biosimilars in the USA. BioDrugs. 2015;29(5):309–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cai XY, et al. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. Bioanalysis. 2012;4(17):2169–77.

    Article  CAS  PubMed  Google Scholar 

  36. Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis. 2013;5(5):561–74.

    Article  CAS  PubMed  Google Scholar 

  37. Meroni PL, et al. New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: a systematic analysis. Autoimmun Rev. 2015;14(9):812–29.

    Article  CAS  PubMed  Google Scholar 

  38. Bendtzen K. Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy. 2012;4(11):1167–79.

    Article  CAS  PubMed  Google Scholar 

  39. Bendtzen K. Immunogenicity of anti-TNF-alpha biotherapies: I. Individualized medicine based on immunopharmacological evidence. Front Immunol. 2015;6:152.

    PubMed  PubMed Central  Google Scholar 

  40. Bendtzen K, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–81.

    Article  CAS  PubMed  Google Scholar 

  41. Weisman MH, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–21.

    Article  CAS  PubMed  Google Scholar 

  42. Chen DY, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):e16.

    Article  PubMed  Google Scholar 

  43. Llinares-Tello F, et al. Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis. Reumatología Clinica. 2014;10(2):105–8.

    Article  PubMed  Google Scholar 

  44. Llinares-Tello F, et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int. 2014;34(12):1701–8.

    Article  CAS  PubMed  Google Scholar 

  45. Bandres Ciga S, et al. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies. J Clin Rheumatol. 2015;21(3):115–9.

    Article  PubMed  Google Scholar 

  46. Jani M, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ). 2015;67(8):2011–9.

    Article  CAS  Google Scholar 

  47. Valor L, et al. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison. Clin Exp Rheumatol. 2015;33(5):617–23.

    PubMed  Google Scholar 

  48. Wolbink GJ, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704–7.

    Article  CAS  PubMed  Google Scholar 

  49. Food and Drug Administration. Guidance for industry: bioanalytical method validation. 2001. http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf. Accessed 24 Nov 2015.

  50. Tovey MG, Lallemand C. Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals. Bioanalysis. 2012;4(17):2179–90.

    Article  CAS  PubMed  Google Scholar 

  51. McCutcheon KM, Quarmby V, Song A. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference. J Immunol Methods. 2010;358(1–2):35–45.

    Article  CAS  PubMed  Google Scholar 

  52. Steenholdt C, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit. 2013;35(4):530–8.

    Article  CAS  PubMed  Google Scholar 

  53. Bender NK, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27(3):269–74.

    Article  CAS  PubMed  Google Scholar 

  54. Bourdage JS, et al. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007;327(1–2):10–7.

    Article  CAS  PubMed  Google Scholar 

  55. Rispens T, et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods. 2012;375(1–2):93–9.

    Article  CAS  PubMed  Google Scholar 

  56. Llinares-Tello F, et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med. 2012;50(10):1845–7.

    Article  CAS  PubMed  Google Scholar 

  57. van Schouwenburg PA, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104–9.

    Article  PubMed  Google Scholar 

  58. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–72.

    Article  PubMed  Google Scholar 

  59. Rispens T, et al. Drug interference in immunogenicity assays depends on valency. J Pharm Biomed Anal. 2013;85:179–85.

    Article  CAS  PubMed  Google Scholar 

  60. Jung SM, et al. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. Int Immunopharmacol. 2014;21(1):20–5.

    Article  CAS  PubMed  Google Scholar 

  61. Chen JS, et al. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken). 2014;66(3):464–72.

    Article  CAS  Google Scholar 

  62. van Schie KA, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74(1):311–4.

    Article  PubMed  Google Scholar 

  63. Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol, 2015; 6.

  64. Mire-Sluis AR, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1–2):1–16.

    Article  CAS  PubMed  Google Scholar 

  65. Bendtzen K, et al. Monitoring immunogenicity of protein-based TNF antagonists. Frontline Gastroenterol. 2015.

  66. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20(4):431–5.

    Article  CAS  PubMed  Google Scholar 

  67. Food and Drug Administration. Guidance for industry: assay development for immunogenicity testing of therapeutic proteins. 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf. Accessed 24 Nov 2015.

  68. European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004007/WC500200380.pdf. Accessed 24 Nov 2015.  

  69. Jolicoeur P, Tacey RL. Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. Bioanalysis. 2012;4(24):2959–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Slovenian Research agency, National Research Programme P3-0314, 2015-2020 (to S.SS., Department of Rheumatology, University Medical Centre Ljubljana, Slovenia).

Author information

Authors and Affiliations

  1. Department of Rheumatology, University Medical Centre-Ljubljana, Vodnikova 62, 1000, Ljubljana, Slovenia

    Manca Ogrič, Matic Terčelj, Sonja Praprotnik, Matija Tomšič, Borut Božič, Snezna Sodin-Semrl & Saša Čučnik

  2. Faculty of Medicine, University of Ljubljana, 1000, Ljubljana, Slovenia

    Matija Tomšič

  3. Chair of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, 1000, Ljubljana, Slovenia

    Borut Božič & Saša Čučnik

  4. Natural Sciences and Information Technologies, Faculty of Mathematics, University of Primorska, 6000, Koper, Slovenia

    Snezna Sodin-Semrl

Authors
  1. Manca Ogrič
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matic Terčelj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonja Praprotnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matija Tomšič
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Borut Božič
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Snezna Sodin-Semrl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Saša Čučnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saša Čučnik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogrič, M., Terčelj, M., Praprotnik, S. et al. Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits. Immunol Res 65, 172–185 (2017). https://doi.org/10.1007/s12026-016-8824-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-016-8824-8

Keywords

Search

Navigation